Protein Kinase Inhibitors: all 15,278 studies that test it

Page 95 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR AlterationsCompletedNCT04258527Phase 1
• Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.Status unknownNCT04258072Phase 1
• Trametinib in the Treatment of Complicated Extracranial Arterial Venous MalformationCompletedNCT04258046Phase 2
• A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)CompletedNCT04258033Phase 2
• Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 RearrangementCompletedNCT04256980Phase 2
• Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and PertuzumabStatus unknownNCT04255056Phase 2
• A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Phase 1/2
• This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in PatientsStatus unknownNCT04254471Phase 2/3
• Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade GliomasStatus unknownNCT04253873Phase 2
• Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer PatientsCompletedNCT04253561Phase 1
• A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT04253262Phase 1/2
• Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsCompletedNCT04249284Phase 1
• Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP)Status unknownNCT04247750Phase 2
• High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)Status unknownNCT04247633Phase 2
• A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRIStatus unknownNCT04247256Phase 1/2
• A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid TumorsCompletedNCT04247126Phase 1
• Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast CancerStatus unknownNCT04246502Phase 2
• Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic SarcomasCompletedNCT04242238Phase 1
• Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCCStatus unknownNCT04241523Phase 2
• Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell TransplantTerminatedNCT04239989Phase 1
• Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine CancerStatus unknownNCT04239443Phase 2
• 9-ING-41 in Pediatric Patients With Refractory Malignancies.TerminatedNCT04239092Phase 1
• A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.WithdrawnNCT04239014Phase 2
• A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene FusionCompletedNCT04238715Phase 2
• Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid CancerActive, not recruitingNCT04238624Phase 2
• A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy VolunteersCompletedNCT04238364Phase 1
• A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.Status unknownNCT04236310Phase 2
• A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)Status unknownNCT04234607Phase 3
• Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaActive, not recruitingNCT04234061Phase 2
• Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell LymphomaWithdrawnNCT04233697Phase 1
• The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I MutationCompletedNCT04233346Phase 2
• Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationCompletedNCT04233021Phase 2
• Anlotinib Treatment in Steroid Depenent/Refractory cGVHDTerminatedNCT04232397Phase 2
• Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and MetforminCompletedNCT04231435Phase 1
• Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical CancerTerminatedNCT04230954Phase 2
• Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04229849Phase 2
• A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based ChemotherapyStatus unknownNCT04229615Phase 3
• Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161Status unknownNCT04228406Phase 1
• Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular CarcinomaStatus unknownNCT04227808Phase 2
• Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)TerminatedNCT04227327Phase 2
• Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLCActive, not recruitingNCT04227028Phase 1
• Clinical Utility of Liquid Biopsy in Brigatinib ALK+ PatientsActive, not recruitingNCT04223596Phase 2
• Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride CapsuleCompletedNCT04223583Phase 4
• CM082 in Patients With Myopic Choroidal Neovascularization (CNV)SuspendedNCT04222842Phase 1
• Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade GliomaWithdrawnNCT04220892Early Phase 1
• A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host DiseaseTerminatedNCT04220632Phase 1/2
• Actuate 1901: 9-ING-41 in MyelofibrosisCompletedNCT04218071Phase 2
• MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue SarcomaCompletedNCT04216953Phase 1/2
• A Study of Anlotinib in Subjects With Advanced MalignancyCompletedNCT04216082Phase 2
• Ribociclib and Spartalizumab in R/M HNSCCStatus unknownNCT04213404Phase 1
• Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery RecurrenceStatus unknownNCT04213118Phase 2
• Anlotinib Combined With Nivolumab for Non-Small Cell Lung CancerStatus unknownNCT04211896Phase 2
• Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract CancersStatus unknownNCT04211168Phase 2
• A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT04210219Phase 1
• A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy VolunteersCompletedNCT04209699Phase 1
• Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersActive, not recruitingNCT04209660Phase 2
• A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative ColitisWithdrawnNCT04209556Phase 2
• JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIMCompletedNCT04208464Phase 2
• Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Phase 2/3
• Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA MutationActive, not recruitingNCT04208178Phase 3
• A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III MelanomaActive, not recruitingNCT04207086Phase 2
• D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCCompletedNCT04206072Phase 2/3
• The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver CancerStatus unknownNCT04204577Phase 2
• A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive MutationCompletedNCT04204473Phase 1
• Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04203485Phase 3
• Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal CancerStatus unknownNCT04202978Phase 1/2
• Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung CancerStatus unknownNCT04201990Phase 1/2
• Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung AdenocarcinomaCompletedNCT04201756Phase 2
• A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF AberrationActive, not recruitingNCT04201457Phase 1/2
• WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System MetastasesActive, not recruitingNCT04197934Phase 1
• Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade GliomasActive, not recruitingNCT04197492Phase 2
• Pembrolizumab With Axitinib in Recurrent Endometrial CancerWithdrawnNCT04197219Phase 2
• Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric CancerCompletedNCT04195828Phase 2
• Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib FailureCompletedNCT04193553Phase 2
• GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal MetastasesActive, not recruitingNCT04192981Phase 1
• Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung CancerStatus unknownNCT04192682Phase 2/3
• Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)Status unknownNCT04191954Phase 2/3
• Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical StudyStatus unknownNCT04190745Phase 2
• Safety and Tolerability of ABM-1310 in Patients With Advanced Solid TumorsTerminatedNCT04190628Phase 1
• Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell LymphomaActive, not recruitingNCT04189757Phase 2
• First-line Chemotherapy for Recurrent Cervical CancerCompletedNCT04188847Phase 2
• Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT04188405Phase 2
• Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)Status unknownNCT04187495Phase 1
• A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the BodyCompletedNCT04187456Phase 1
• A MolEcularly Guided Anti-Cancer Drug Off-Label TrialActive, not recruitingNCT04185831Phase 2
• Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal MelanomaWithdrawnNCT04184518Phase 2
• MAX-40279-01 in Patients With Advanced Solid TumorsStatus unknownNCT04183764Phase 1
• Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04182724Phase 1/2
• A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung CancerStatus unknownNCT04181372Phase 2
• Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid CancersStatus unknownNCT04180007Phase 2
• The Basket Study of Pyrotinib Maleate for HER2-Postive Solid TumorStatus unknownNCT04179656Phase 2
• Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal CancerStatus unknownNCT04179084Phase 2
• A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With FamotidineCompletedNCT04179071Phase 1
• Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic LeukemiaCompletedNCT04178798Phase 3
• PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric CancerStatus unknownNCT04174339Not applicable
• Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell LymphomaStatus unknownNCT04173455Phase 1
• Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant MesotheliomaTerminatedNCT04173338Phase 1
• Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue SarcomaCompletedNCT04172805Phase 2
• Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic CancerSuspendedNCT04172532Phase 1/2
• Study of Zanubrutinib in Japanese Participants With B-Cell MalignanciesCompletedNCT04172246Phase 1/2

← Protein Kinase Inhibitors overview